Accenture: strategic investment in Earli
(CercleFinance.com) - Accenture announced on Monday that it had made a strategic investment in Earli Inc, a US biotechnology company specializing in the early detection of cancer.
Based in Redwood City (California), Earli develops programmable genetic elements to identify the presence of active cancer cells at an early stage.
Earli's synthetic biopsy method represents a step-change in early cancer detection technologies, and will bring significant benefits to biopharmaceutical companies by improving the accuracy and efficacy of new treatments and diagnostic tools, and providing a better understanding of the mechanisms of cancer progression, Accenture Life Sciences explains.
Accenture specifies that its investment in Earli is part of the 'Project Spotlight' program of its private equity subsidiary Accenture Ventures, aimed at investing in companies offering disruptive technologies.
The financial terms of the transaction were not disclosed.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Based in Redwood City (California), Earli develops programmable genetic elements to identify the presence of active cancer cells at an early stage.
Earli's synthetic biopsy method represents a step-change in early cancer detection technologies, and will bring significant benefits to biopharmaceutical companies by improving the accuracy and efficacy of new treatments and diagnostic tools, and providing a better understanding of the mechanisms of cancer progression, Accenture Life Sciences explains.
Accenture specifies that its investment in Earli is part of the 'Project Spotlight' program of its private equity subsidiary Accenture Ventures, aimed at investing in companies offering disruptive technologies.
The financial terms of the transaction were not disclosed.
Copyright (c) 2024 CercleFinance.com. All rights reserved.